Literature DB >> 33546228

Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists.

Angel A T Uchiyama1, Pedro A I A Silva1, Moisés S M Lopes1, Cheng T Yen1, Eliza D Ricardo1, Taciana Mutão1, Jefferson R Pimenta1, Larissa M Machado1, Denis S Shimba1, Renata D Peixoto2.   

Abstract

Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide, including among cancer patients. However, drug-drug interactions between PPIs and other agents may lead to decreased drug absorption with possible reduced therapeutic benefit, or even increased toxicity. Unfortunately, only scarce data exist regarding the safety of concomitant PPI use with anti-cancer agents. We aim at reviewing current evidence on this possible interaction by dividing anti-cancer agents by class. Until further data is available, we encourage healthcare providers to limit unnecessary PPI overuse.

Entities:  

Keywords:  chemotherapy; drug-drug interaction; immunotherapy; proton pump inhibitors; tyrosine kinase inhibitors

Year:  2021        PMID： 33546228      PMCID： PMC7985775          DOI： 10.3390/curroncol28010076

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  96 in total

1.  Oral cancer chemotherapy: the promise and the pitfalls.

Authors:  H L McLeod; W E Evans
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

2.  Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.

Authors:  Karl Lewis; Axel Hauschild; James Larkin; Antoni Ribas; Keith T Flaherty; Grant A McArthur; Brigitte Dréno; Edward McKenna; Qian Zhu; Yong Mun; Paolo A Ascierto
Journal:  Eur J Cancer       Date:  2019-06-04       Impact factor: 9.162

3.  Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.

Authors:  Olivier Mir; Nathan Touati; Michela Lia; Saskia Litière; Axel Le Cesne; Stefan Sleijfer; Jean-Yves Blay; Michael Leahy; Robin Young; Ron H J Mathijssen; Nielka P Van Erp; Hans Gelderblom; Winette T Van der Graaf; Alessandro Gronchi
Journal:  Clin Cancer Res       Date:  2019-02-14       Impact factor: 12.531

4.  Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.

Authors:  Raoul Santucci; Dominique Levêque; Véronique Kemmel; Patrick Lutz; Anne-Cécile Gérout; Aurélia N'guyen; Aurélie Lescoute; Francis Schneider; Jean-Pierre Bergerat; Raoul Herbrecht
Journal:  Anticancer Res       Date:  2010-03       Impact factor: 2.480

5.  Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.

Authors:  A Farley; L D Wruble; T J Humphries
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

6.  Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed?

Authors:  F Ranchon; N Vantard; A Gouraud; V Schwiertz; E Franchon; B N Pham; T Vial; B You; F Bouafia; G Salles; C Rioufol
Journal:  Chemotherapy       Date:  2011-05-18       Impact factor: 2.544

Review 7.  TRK inhibitors in TRK fusion-positive cancers.

Authors:  A Drilon
Journal:  Ann Oncol       Date:  2019-12-24       Impact factor: 32.976

8.  Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.

Authors:  Michael P Chu; J Randolph Hecht; Dennis Slamon; Zev A Wainberg; Yung-Jue Bang; Paulo M Hoff; Alberto Sobrero; Shukui Qin; Karen Afenjar; Vincent Houe; Karen King; Sheryl Koski; Karen Mulder; Julie Price Hiller; Andrew Scarfe; Jennifer Spratlin; Yingjie J Huang; Saba Khan-Wasti; Neil Chua; Michael B Sawyer
Journal:  JAMA Oncol       Date:  2017-06-01       Impact factor: 31.777

Review 9.  Axitinib for the management of metastatic renal cell carcinoma.

Authors:  Bernard Escudier; Martin Gore
Journal:  Drugs R D       Date:  2011

Review 10.  FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management.

Authors:  Isabelle Solassol; Frédéric Pinguet; Xavier Quantin
Journal:  Biomolecules       Date:  2019-10-30
View more
  9 in total

Review 1.  Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Authors:  Yang Yang; Shuo Li; Yujiao Wang; Yi Zhao; Qiu Li
Journal:  Signal Transduct Target Ther       Date:  2022-09-17

2.  In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets.

Authors:  Deanna M Mudie; Aaron M Stewart; Jesus A Rosales; Molly S Adam; Michael M Morgen; David T Vodak
Journal:  Pharmaceutics       Date:  2021-08-13       Impact factor: 6.321

Review 3.  Concomitant Gastric Acid Suppressants on the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis.

Authors:  Jun Xia; Jiping Zhu; Lei Li; Shiqin Xu
Journal:  Int J Clin Pract       Date:  2022-01-31       Impact factor: 3.149

4.  Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs.

Authors:  Deanna M Mudie; Aaron M Stewart; Jesus A Rosales; Nishant Biswas; Molly S Adam; Adam Smith; Christopher D Craig; Michael M Morgen; David T Vodak
Journal:  Pharmaceutics       Date:  2021-04-15       Impact factor: 6.321

Review 5.  Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper.

Authors:  Jean-Luc Raoul; Julien Edeline; Victor Simmet; Camille Moreau-Bachelard; Marine Gilabert; Jean-Sébastien Frénel
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

6.  An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.

Authors:  Chaoxing Liu; Huaijuan Guo; Haiyan Mao; Jiandong Tong; Mengxue Yang; Xuebing Yan
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

Review 7.  Proton Pump Inhibitors and Cancer: Current State of Play.

Authors:  Marie Bridoux; Nicolas Simon; Anthony Turpin
Journal:  Front Pharmacol       Date:  2022-03-14       Impact factor: 5.810

Review 8.  Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid Tumors.

Authors:  Stanislav Kalinin; Anna Malkova; Tatiana Sharonova; Vladimir Sharoyko; Alexander Bunev; Claudiu T Supuran; Mikhail Krasavin
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

9.  Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations.

Authors:  Jerry Li; Dana Nickens; Keith Wilner; Weiwei Tan
Journal:  Oncol Ther       Date:  2021-06-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.